PEGylated Aspergillus flavus uricase boosts thermal stability 16% and cuts immune activation in vitro.
Background
Despite the therapeutic potential of protein and peptide-based drugs, their clinical utility is often hampered by rapid metabolic clearance and significant immunogenicity, leading to reduced efficacy and adverse reactions. Hyperuricemia, a metabolic disorder characterized by elevated uric acid levels, is a precursor to conditions like gout, kidney damage, and cardiovascular diseases. Uricase (Uox) enzymes, which convert uric acid into more soluble allantoin, represent a promising treatment for hyperuricemia, but native forms suffer from poor stability and high immunogenicity, necessitating strategies like PEGylation to improve their pharmacological profile.
Study Design
Researchers synthesized methoxy polyethylene glycol (5 kDa) activated with Succinimidyl Succinamide (mPEG-SS) through a two-step reaction, confirming its structure via FT-IR, 1H-NMR, and TLC. This mPEG-SS was then conjugated to Aspergillus flavus-derived uricase (Uox) at a 1:10 molar ratio (Uox:mPEG-SS). Successful conjugation was verified using DLS and SDS-PAGE. The study compared the kinetic behavior, thermodynamic stability, and immunogenic potential of native versus PEGylated uricase using kinetic assays, thermal denaturation studies, and in vitro immunological evaluations. Immunogenicity was assessed by CFSE-labeled PBMC proliferation and cytokine profiling via ELISA.
Results
PEGylation significantly enhanced the stability of uricase, demonstrating a 16.44% increase in thermal stability and a 23.37% increase in half-life at 45°C compared to the native enzyme. This improvement came with only a modest 27.3% reduction in catalytic efficiency, attributed to steric hindrance. Crucially, in vitro immunogenicity assays revealed a substantial reduction in immune activation: > PEGylated uricase induced significantly lower immune cell proliferation and cytokine release (p < 0.0045) compared to the native enzyme, with its immunogenic response being statistically indistinguishable from the control group (p = 0.2426). These findings underscore the potential of PEGylation to mitigate key limitations of protein therapeutics.
Key Findings
- PEGylation increased uricase thermal stability by 16.44%.
- PEGylated uricase half-life at 45°C increased by 23.37%.
- Catalytic efficiency of PEGylated uricase was reduced by a modest 27.3%.
- PEGylated uricase induced significantly lower immune activation (p < 0.0045) compared to native uricase.
- Immunogenic response of PEGylated uricase was not statistically different from control (p = 0.2426).
Why It Matters
This study provides compelling evidence that PEGylation with 5 kDa mPEG-SS dramatically improves the therapeutic profile of uricase, addressing critical issues of stability and immunogenicity that limit native protein drugs. For individuals managing hyperuricemia and gout, this could pave the way for more effective and safer enzyme replacement therapies, potentially reducing the frequency of adverse immune reactions and improving drug half-life. While these are in vitro findings, they suggest that future preclinical and clinical development of PEGylated uricase could lead to a more tolerable and potent treatment option, potentially influencing dosing regimens and patient compliance by extending drug circulation time and reducing immunogenic responses.
uricase
pegylation
hyperuricemia
gout
protein-stability
immunomodulation